disodium ethydronate , ≥98.0% , 7414-83-7
Synonym(s):
1-Hydroxyethane-1,1-bisphosphonic acid disodium salt;Dihydrogen (1-hydroxyethylidene)bisphosphonate disodium hydrate
CAS NO.：7414-83-7
Empirical Formula: C2H9NaO7P2
Molecular Weight: 230.02
MDL number: MFCD00152567
EINECS: 231-025-7
| Pack Size | Price | Stock | Quantity |
| 1g | RMB127.20 | In Stock |
|
| 5G | RMB272.80 | In Stock |
|
| 25G | RMB789.60 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | >300 °C |
| storage temp. | 15-25°C |
| solubility | H2O: 26 mg/mL |
| form | solid |
| color | white |
| Water Solubility | Soluble in water (26 mg/ml). |
| Merck | 14,3863 |
| Stability: | Hygroscopic |
| CAS DataBase Reference | 7414-83-7 |
| EPA Substance Registry System | Phosphonic acid, (1-hydroxyethylidene)bis-, disodium salt (7414-83-7) |
Description and Uses
Agents in the first generation (e.g., etidronate disodium and tiludronate) that were dosed continuously produced poorly mineralized bone, because there was no interval for appropriate bone mineralization to occur. Subsequent studies that used a cyclic dosing schedule (400 mg/day for 2 weeks, followed by 2.5 months of calcium supplementation only) showed improvement in bone mineralization. Etidronate has been approved for treatment of Paget's disease of the bone but not for treatment of osteoporosis. Tiludronate is approximately 10-fold more potent than etidronate and, when given orally for 6 months (200, 400, or 800 mg/day), increases BMD by 2%. No further bone loss was detected in patients 6 months after cessation of therapy.
Sequestering and chelating agent; scale and corrosion inhibitor.
